Why the study?
Despite strong scientific evidence for cardiovascular pharmacogenetics, barriers persist that prevent its implementation into daily clinical practice.
This review discusses the evidence and guidelines for implementing pharmacogenetic testing for clopidogrel, warfarin, acenocoumarol, and simvastatin in daily clinical practice.
Answers are grounded in this paper and cite their sources.
Supports pharmacogenetics for cardiology drugs; leaves open translation of evidence into routine practice.
There is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this integration. A large part of these pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral drugs. However, the scientific evidence is also high for other drugs used in other medical areas, for example, in cardiology. In this article, we discuss the evidence and guidelines currently available on pharmacogenetics for clopidogrel, warfarin, acenocoumarol, and simvastatin and its implementation in daily clinical practice.
No takes yet. Share an insight, caveat, or question.
Dávila-Fajardo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: